Heather Kostner

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

I. Bernstein, P. Burke, R. Walter, 2013, Blood.

Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.

D. Benjamin, K. Gordon, H. V. Van Epps, 2017, Blood.

SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

A. Nesterova, D. Benjamin, Leia M. Smith, 2014, Molecular Cancer Therapeutics.